TY - JOUR. T1 - Standardizing measurement of chronic obstructive pulmonary disease exacerbations. T2 - Reliability and validity of a patient-reported diary. AU - Leidy, Nancy Kline. AU - Wilcox, Teresa K.. AU - Jones, Paul W.. AU - Jones, Paul. AU - Roberts, Laurie. AU - Powers, John H.. AU - Sethi, Sanjay. AU - Donohue, James. AU - Eremenco, Sonya. AU - Erickson, Penny. AU - Martinez, Fernando. AU - Patrick, Donald. AU - Rennard, Stephen. AU - Rodriguez-Roisin, Roberto. AU - Schünemann, Holger. PY - 2011/2/1. Y1 - 2011/2/1. N2 - Rationale: Although exacerbations are an important problem in chronic obstructive pulmonary disease (COPD) and a target of intervention, there is no valid, standardized tool for assessing their frequency, severity, and duration. Objectives: This study tested the properties of the Exacerbations of Chronic Pulmonary Disease Tool (EXACT), a new patient-reported outcome diary. Methods: A prospective, two-group, observational study was conducted in patients with COPD. The ...
The article presents four abstracts on medical research in pulmonary disease. They are "Efficacy and Organization of Early Discharge Schemes for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Analysis from the 2nd UK Corp Audit," by S.J. Quantrill, H. Hosker, K. Anstey, D. Lowe and C.M. Roberts, and "The Warm Study: A Case Control Study of the Risk Factors for Hospital Admission in the Winter Among the Elderly With Acute Respiratory Disease," by R.E. Jordan, K.K. Cheng, J.I. Hawker, B. Olowokure, J.G. Ayres and W. Tunnicliffe ...
The purpose of this study is to determine whether there is a statistical association between the changes from baseline in the levels of two cytokines interleukin (IL)-17A and IL-6 in the sputum of patients with chronic obstructive pulmonary disease (COPD) and the severity of acute exacerbations of COPD (AE-COPD). These sputum cytokine levels are taken as measures of the adaptive immune response (IL-17A) and the innate immune response (IL-6), respectively. Sputum will be collected either spontaneously or will be obtained by induction; cytokine levels will be measured by ELISA. The primary analysis, comparisons of sputum cytokine levels between clinical states, will be done using random effects modeling ...
"Evidence-based, guideline-recommended practices improve multiple outcomes in patients admitted with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), but are incompletely implemented in actual practice..."
Medicine Journal in MJB authors are : Amjed Hassan Abbas,Samir Sawadi Hammuod Impact Of Hypoxemia In Patient With Chronic Obstructive Pulmonary Disease On Renal Function Tests university of babylon journals in the repository for farther content please log to http://repository.uobabylon.edu.iq
Ambrosino N, Palmiero G, Strambi SK. New approaches in pulmonary rehabilitation. Clin Chest Med. 2007 Sep;28(3):629-38, vii. Review.. Bartolome R. Update on the management of COPD. Chest. 2008;133(6).. Booker R. Chronic obstructive pulmonary disease. Part two--management. Nurs Times. 2007 May 1-7;103(18):28-9.. Bourjeily G, Rochester CL. Exercise training in chronic obstructive pulmonary disease. Clin Chest Med. 2000;21(4):763-81.. Cahalin LP, Braga M, Matsuo Y, Hernandez ED. Efficacy of diaphragmatic breathing in persons with chronic obstructive pulmonary disease: a review of the literature. J Caridopulm Rehabil. 2002;22(1):7-21.. Chuck A, Jacobs P, Mayers I, Marciniuk D. Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease. Can Respir J. 2008;15(8):437-43.. Collins EG, Langbein WE, Fehr L, Maloney C. Breathing pattern retraining and exercise in persons with chronic obstructive pulmonary disease. AACN Clin Issues. 2001;12(2):202-9.. Coyle ME, Shergis JL, Huang ET, ...
A 65-year-old man with a history of obesity and severe chronic obstructive pulmonary disease presents to the emergency room with increasing shortness of breath and a productive cough. A chest x-ray shows changes of chronic obstructive pulmonary disease but no acute pathology. It is felt that he has a chronic obstructive pulmonary disease exacerbation and is begun on antibiotics, steroids, and albuterol inhalers. Several minutes after presenting, his heart rate is noted to increase and become irregular. An ECG is obtained.. What is the diagnosis? ...
Background Patients with chronic obstructive pulmonary disease (COPD) have few options for treatment. The effi cacy and safety of the phosphodiesterase-4 inhibitor rofl umilast have been investigated in studies of patients with moderate-to-severe COPD, but not in those concomitantly treated with longacting inhaled bronchodilators. The eff ect of rofl umilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated. Methods In two double-blind, multicentre studies done in an outpatient setting, after a 4-week run-in, patients older than 40 years with moderate-to-severe COPD were randomly assigned to oral rofl umilast 500 μg or placebo once a day for 24 weeks, in addition to salmeterol (M2-127 study) or tiotropium (M2-128 study). The primary endpoint was change in prebronchodilator forced expiratory volume in 1 s (FEV1). Analysis was by intention to treat. The studies are registered with ClinicalTrials.gov, ...
Chronic Obstructive Pulmonary Disease (COPD) represents one of the most challenging chronic diseases of the 21st century: it is expected to be the fourth leading cause of death by 2030. COPD is characterized by pulmonary and extra-pulmonary systemic manifestations caused by partly irreversible expiratory airflow obstruction. The cornerstone of COPD management is the prescription of single or combined inhalation therapy, such as short- and long-acting bronchodilators, inhaled corticosteroids to possibly prevent disease progression, preserve lung function, relieve respiratory symptoms and prevent or treat exacerbations. Given the complex and lifelong treatment, one can expect that adherence to the prescribed inhalation therapy is not self-evident. Adherence can be defined as the the extent to which a persons behaviour (taking medications, following a recommended diet and/or executing life-style changes) corresponds with the agreed recommendations of a health care provider. Inhaled medications ...
During the last 25 years, the use of non-invasive ventilation has grown substantially. Non-invasive ventilation refers to the delivery of positive pressure to the lungs without endotracheal intubation and plays a significant role in the treatment of patients with acute respiratory failure and in the domiciliary management of some chronic respiratory and sleep disorders. In the intensive and acute care setting, the primary aim of non-invasive ventilation is to avoid intubation, and it is mainly used in patients with chronic obstructive pulmonary disease exacerbations, acute cardiogenic pulmonary oedema, immunocompromised or in the context of weaning, situations in which a reduction in mortality has been demonstrated. The principal techniques are continuous positive airway pressure, bilevel pressure support ventilation and more recently, high flow nasal cannula. Whereas non-invasive pressure support ventilation requires a ventilator, the other two techniques are simpler and can be easily used in non
Background. Patients hospitalized for heart failure (HF) are at high risk of readmission. Chronic obstructive pulmonary disease (COPD) is one of the most prevalent comorbidities in this population. However, few data and only small studies describe the impact of COPD on the risk of readmission.. Methods and results. Hospitalizations for HF were identified in the 2012 National Readmissions Database. We compared clinical characteristics and the risk of all-cause, cardiovascular (CV) and respiratory-related readmission for patients with and without COPD. We included 225,160 patients hospitalized for HF among whom 54,953 had comorbid COPD. Patients with COPD were younger (median age 76 years COPD versus 77 years without COPD; p , 0.001), had a higher burden of comorbidity and were more frequently male (53% versus 49%, p , 0.001). Thirty-day all-cause readmission risk was two-fold greater in patients with COPD compared to those without COPD (adjusted HR 2.02, 95%CI 1.97-2.08). Most readmissions were ...
BACKGROUND: The beneficial effects of pharmacotherapy for chronic obstructive pulmonary disease (COPD) are well established. However, there are few data for treatment in the early stages of the disease. We examined the effect of tiotropium on outcomes in a large subgroup of patients with moderate COPD. METHODS: The Understanding Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) study was a randomised, double-blind, placebo-controlled trial undertaken in 487 centres in 37 countries. 5993 patients aged 40 years or more with COPD were randomly assigned to receive 4 years of treatment with either once daily tiotropium (18 mug; n=2987) or matching placebo (n=3006), delivered by an inhalation device. Randomisation was by computer-generated blocks of four, with stratification according to study site. In a prespecified subgroup analysis, we investigated the effects of tiotropium in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II disease. Primary ...
SAN DIEGO -- Statins dont prevent chronic obstructive pulmonary disease exacerbations or improve outcomes in sepsis-related respiratory failure, a series of trials showed. For patients with acute respiratory distress syndrome (ARDS) from sepsis in the ICU, rosuvastatin (Crestor) didnt cut 60-day in-hospital mortality compared with placebo (28.5% versus 24.9%, P=0.21) or boost ventilator-free days (mean 15.1 in both groups, P=0.96 ...
The Adjunctive Effect of Nebulized Furosemide in Acute Treatment of Patients with Chronic Obstructive Pulmonary Disease Exacerbation: A. Hypothesis that nebulizer furosemide might work in COPD came form some early studies suggesting it could modulate vagal afferent activity in. Three terminal cancer patients with severe dyspnea were treated with nebulized furosemide. The underlying causes of dyspnea varied. ...
Dinesen, B., Haesum, LKE, Soerensen, N., Nielsen, C., Grann, O., Hejlesen, O., Toft, E., & Ehlers, L. (2012). Using preventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients. Journal of Telemedicine and Telecare, 18(4): 221-225.. Lewis et al. (2010b), Home telemonitoring and quality of life in stable, optimised chronic obstructive pulmonary disease, Journal of Telemedicine and Telecare, 16: 253-259. Lewis, K.E.; Annandale, J.A.; Warm, D.L.; Rees, S.E.; Hurlin, C.; Blyth, H; Syed, Y; Lewis, L. (2010a). Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 7:44-50. Liu et al. (2008), Efficacy of a cell phone-based exercise programme for COPD, European Respiratory Journal, 32 (3): 651-659. Mair et al. (2005). Patient and provider perspectives on telecare: Preliminary results ...
Clinical trial for COPD (Chronic Obstructive Pulmonary Disease) , A Phase 4 clinical study for patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) who experience COPD exacerbations.
Hello, are you looking for article Chronic obstructive pulmonary disease COPD is one of the most common ? If it is true we are very fortunate in being able to provide information Chronic obstructive pulmonary disease COPD is one of the most common And good article Chronic obstructive pulmonary disease COPD is one of the most common This could benefit/solution for you. ...
Hello, are you looking for article 10 NANDA COPD Chronic Obstructive Pulmonary Disease , Nanda Books? If it is true we are very fortunate in being able to provide information 10 NANDA COPD Chronic Obstructive Pulmonary Disease , Nanda Books And good article 10 NANDA COPD Chronic Obstructive Pulmonary Disease , Nanda Books This could benefit/solution for you. ...
Diseases of the respiratory system, including chronic obstructive pulmonary disease (COPD), were the third leading cause of hospitalizations in Simcoe Muskoka in 2017. There were more than 1,500 COPD hospitalizations in 2017, accounting for more than one-third of all respiratory system disease related hospitalizations.. The age-standardized hospitalization rate for COPD in Simcoe Muskoka for all ages and sexes in 2017 was 217 (206.1, 228.1) hospitalizations per 100,000 population, which was significantly higher than the Ontario rate of 177 (174.9, 179.0) hospitalizations per 100,000 population. There was a small but significant decreasing trend in the COPD hospitalization rates in Simcoe Muskoka over the 15-year period from 2003 to 2017. The provincial rates for COPD hospitalizations did not change significantly over this same period of time. The COPD hospitalization rates in Simcoe Muskoka have been consistently above the provincial rates over this time period; however, the gap has narrowed in ...
MICHAEL F. EASLEY GOVERNOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AWARENESS MONTH 2007 BY THE GOVERNOR OF THE STATE OF NORTH CAROLINA A PROCLAMATION WHEREAS, the state of North Carolina has long been concerned with the health of its citizens; and WHEREAS, chronic lung diseases, known collectively as chronic obstructive pulmonary disease. are the fourth leading cause of death in the United States; with over 119,000 Americans dying from this disease each year: and WHEREAS, chronic obstructive pulmonary diseases costs the United States an estimated $31.9 billion a year; and WHEREAS, 16 million people in the United States have been diagnosed with some form of COPD with a similar number undiagnosed; and WHEREAS, awareness, early detection and treatment are crucial in the prevention or slowing of the spread of lung disease in this country; and WHEREAS, the citizens of North Carolina deserve the opportunity to grow, thrive, be healthy and be informed and aware of their respiratory health and of d1e ...
Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation Ellen Tufvesson, Leif Bjermer, Marie Ekberg Respiratory Medicine and Allergology, Department of Clinical Sciences, Lund University, Lund, Sweden Background: Some patients with chronic obstructive pulmonary disease (COPD) show increased airway inflammation and bacterial colonization during stable phase. The aim of this study was to follow COPD patients and investigate chronic colonization with pathogenic bacteria during stable disease phase, and relate these findings to clinical parameters, inflammatory pattern, lung function, and exacerbations. Methods: Forty-three patients with COPD were included while in a stable state and followed up monthly until exacerbation or for a maximum of 6 months. The patients completed the Clinical COPD Questionnaire and Medical Research Council dyspnea scale questionnaires, and exhaled breath condensate
... is a chapter in the book, Pulmonology, containing the following 11 pages: Alpha-1-Antitrypsin Deficiency, Medications in COPD Management, COPD Action Plan, COPD Exacerbation Prevention, COPD Exacerbation Antibiotics, COPD Staging, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema, COPD Management, Acute Exacerbation of Chronic Bronchitis.
The prevalence of osteoporosis is high in chronic obstructive pulmonary disease (COPD) patients. The gold standard for the diagnosis of osteoporosis is bone mineral density (BMD) measurements as assessed by dual energy absorptiometry (DXA) scanning a
Chronic obstructive pulmonary disease (COPD) is one of the highest ranking diseases with regard to prevalence and mortality in Korea and also worldwide. In the past decade, effective inhaler medications for COPD treatment have been developed or approved. These inhaler medications have been proven to have beneficial effects on symptoms, lung function, quality of life, exercise capacity, and exacerbation. The inhalers used widely are long-acting anticholinergics, long-acting beta2-agonists, and combined inhalers of a corticosteroid and long-acting beta2-agonist. These inhaler medications are more effective than oral medications and less likely to produce adverse events. However, the inhaler medications should be used appropriately to achieve the desired effect. For COPD patients with a forced expiratory volume in 1 second (FEV1) less than 80% of the predicted value, a long-acting anticholinergic or long-acting beta2-agonist is usually the medication of first choice. If a COPD patient with a FEV1 ...
1. Wilson, M, Swank, AM & Felker, J. Exercise strategies for the individual with chronic obstructive pulmonary disease. Strength & Conditioning Journal. 26(3): 58-63, 2004. 2. Kortianou EA, Nasis IG, Spetsioti ST, Daskalakis AM, Vogiatzis I. Effectiveness of interval exercise training in patients with COPD. Cardiopulmonary Pysical Therapy Journal. 21(3):12-19, 2010. 3. Vogiatzis, I, Nanas, S & Roussos, C. Interval training as an alternative modality to continous exercise in patients with COPD. European Respiratory Journal. 20:12-19, 2002. 4. Vogiatzis, I, Nanas, S, Kastanakis, E, Georgiadou, O, Papazahou, O & Roussos, C. Dynamic hyperinflation and tolerance to interval exercise in patients with advanced COPD. European Respiratory Journal. 24: 385-390, 2004. 5. Leung, RWM, Alison, JA, McKeough, ZJ, Peters MJ. Ground walk training improves functional exercise capacity more than cycle training in people with chronic obstructive pulmonary disease (COPD): a randomised trial. Journal of Physiotherapy ...
1. Some patients with the emphysematous type of tobacco-related chronic obstructive pulmonary disease are hypermetabolic. Since the likely mechanism is the increased work of breathing, other groups of patients with chronic obstructive pulmonary disease should be similar. We have now measured basal metabolic rate and diet-induced thermogenesis in six patients with chronic obstructive pulmonary disease with an arterial partial pressure of CO2 of ,5kPa (emphysematous), nine patients with chronic obstructive pulmonary disease with an arterial partial pressure of CO2 of ,6kPa (bronchitic), eight patients with chronic obstructive pulmonary disease due to chronic asthma and seven control subjects. Diet-induced thermogenesis was measured for 4h after a meal of 87% carbohydrate, 11% protein and 2% fat as energy, with a total energy content of 40% of basal metabolic rate.. 2. There was no difference between measured and predicted basal metabolic rate in the control (5541 ± 272 versus 5881 ± 245 kJ/24h) ...
AIM: This paper is a report of a study to describe the essential structure of the lived experience of living with severe chronic obstructive pulmonary disease (COPD) during the palliative phase of the disease. BACKGROUND: Chronic obstructive pulmonary disease is one of the most common diseases throughout the world. Shortness of breath, fatigue and cough are the most troublesome symptoms, and living with COPD often imposes limitations on daily living. The disease has a great impact on quality of life and affects the extent to which people can be active in daily life. METHODS: We conducted qualitative interviews of eight people with COPD and collected data over a 2-month period in 2003. Our patients were recruited from two pulmonary disease clinics in West Sweden. We used a phenomenological methodology to analyse the interviews. FINDINGS: Daily life for people with COPD is affected in several different ways. The patients described how their physical limitations forced them to refrain from ...
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ ...
The benefits of exercise training for patients with chronic obstructive pulmonary disease (COPD) are well-documented. In South Africa, exercise programmes for COPD patients are limited and often expensive and inaccessible to the broader community. The purpose of this study was to assess the responses of COPD patients to an exercise programme and to determine if the same results can be obtained through a less costly programme. In the primary programme of the study, 22 subjects were subjected to 12 weeks of exercise training. Each subject underwent comprehensive pre- and post-intervention assessments, which included the measurement of overall health status by a physician, level of dyspnoea, forced expiratory lung function, exercise capacity, body mass index and health-related quality of life. Exercise sessions included aerobic and strength training exercises and involved three, hour-long exercise sessions a week. In the modified programme, 18 subjects were randomly divided into an experimental and ...
A doença pulmonar obstrutiva crónica (DPOC) é uma das doenças inflamatórias mais comuns das vias aéreas e uma das principais causas de morbidade e mortalidade em todo o mundo. A doença é caracterizada por uma limitação persistente do fluxo aéreo, geralmente progressiva. As respostas inflamatórias crónicas e imunes desempenham papéis fundamentais no desenvolvimento e progressão da DPOC. A inflamação é uma resposta protetora normal, mas na DPOC esta inflamação é amplificada. Várias células inflamatórias, seus mediadores e enzimas participam na resposta inflamatória na DPOC. A reabilitação respiratória é um componente fundamental da gestão da doença pulmonar obstrutiva crónica. Ela é projetada para melhorar a condição física e psicológica de pessoas com doenças respiratórias crónicas e para promover a adesão a longo prazo do comportamento que melhora a saúde. O objetivo principal deste trabalho foi contribuir para a compreensão do papel das células iNKT ...
Chronic obstructive pulmonary disease (COPD), a.k.a. chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic airflow limitation (CAL) and chronic obstructive respiratory disease (CORD), is the occurrence of chronic bronchitis and emphysema together. This pair work together to narrow the airways of the lungs leading to breathing problems. The disease is under-diagnosed and under-treated. Smoking tobacco smoking is one of the major causes as is exposure to smoke from coal and wood used as domestic fuels.. In contrast to asthma, breathing problems in COPD are poorly reversible even with powerful bronchodilators and the condition worsens over time. BusinessWire reports that the market for COPD drugs will increase from approximately $8.3 billion in 2010 to more than $13.4 billion by 2020. A lateral part of the market is, of course, influenza vaccination. Most healthcare practitioners recommend that COPD patients receive an annual flu jab. Among the companies hoping ...
A total of 267 clinically stable chronic obstructive pulmonary disease (COPD) patients provided complete data about diet and oxidative stress markers in order to assess the relationship between antioxidant rich food groups and nutrients, and serum ma
Title: Cytokines in the Pathogenesis of Chronic Obstructive Pulmonary Disease. VOLUME: 9 ISSUE: 1. Author(s):P. T. Reid and J.- M. Sallenave. Affiliation:Rayne Laboratory, Centre for Inflammation Research, Edinburgh University Medical School, Edinburgh, EH8 9AG, UK. Keywords:Cytokines, Pulmonary Disease, hypersecretion, gene therapy. Abstract: Chronic obstructive pulmonary disease (COPD) is a common cause of morbidity and mortality. The term is heterogenous and encompasses a number of distinct but often overlapping phenotypes including chronic bronchitis, small airways obstruction, emphysema and in some individuals, a systemic component. Although there have been significant advances in understanding the pathophysiology of COPD, understanding of the role of the inflammation in the pathogenesis of the condition remains in its infancy. Indeed, cytokines that are known to orchestrate the inflammatory response in asthma and other inflammatory diseases are only beginning to be reported in COPD. In ...
Risk factors for chronic obstructive pulmonary disease among never-smokers in Korea Seok Jeong Lee,1 Seo Woo Kim,1 Kyoung Ae Kong,2 Yon Ju Ryu,1 Jin Hwa Lee,1 Jung Hyun Chang1 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, 2Department of Clinical Trial Center, School of Medicine, Ewha Womans University, Seoul, Republic of Korea Background: Chronic obstructive pulmonary disease (COPD) patients include those who have never smoked. However, risk factors other than smoking in never-smokers have not been elucidated sufficiently. This study investigated the risk factors for COPD among never-smokers in Korea using population-based data. Methods: The data were retrieved from the Korean National Health and Nutrition Survey IV conducted from 2007 to 2009. Among subjects aged 40 years or older who underwent appropriate pulmonary function tests, never-smokers not diagnosed with asthma and not showing a restrictive pattern on pulmonary function tests were enrolled. Risk factors
TY - JOUR. T1 - Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. AU - Rybak, Debbie. AU - Fallon, Michael B.. AU - Krowka, Michael Joseph. AU - Brown, Robert S.. AU - Reinen, Jenna. AU - Stadheim, Linda. AU - Faulk, Dorothy. AU - Nielsen, Carrie. AU - Al-Naamani, Nadine. AU - Roberts, Karl. AU - Zacks, Steven. AU - Perry, Ted. AU - Trotter, James. AU - Kawut, Steven M.. AU - Okun, Jeffrey. AU - Rabinowitz, Daniel. AU - Horn, Evelyn M.. AU - Rosenthal, Lori. AU - Olsen, Sonja. AU - Shah, Vijay. AU - Wiesner, Russell. AU - Bynon, J. Stevenson. AU - Eckhoff, Devin. AU - Singh, Harpreet. AU - Tanikella, Rajasekhar. AU - Benza, Raymond L.. AU - Wille, Keith. AU - Forman, Lisa. AU - Badesch, David. AU - Shrestha, Roshan. AU - Taichman, Darren B.. AU - Ahya, Vivek. AU - Palevsky, Harold. AU - Reddy, Rajender. AU - Kaplowitz, Neil. AU - Knowles, James. PY - 2008/9. Y1 - 2008/9. N2 - Chronic obstructive pulmonary disease (COPD) may cause ...
Antimicrobial proteins and peptides (AMPs) are a central component of the antibacterial activity of airway epithelial cells. It has been proposed that a decrease in antibacterial lung defense contributes to an increased susceptibility to microbial infection in smokers and patients with chronic obstructive pulmonary disease (COPD). However, whether reduced AMP expression in the epithelium contributes to this lower defense is largely unknown. We investigated the bacterial killing activity and expression of AMPs by air-liquid interface-cultured primary bronchial epithelial cells from COPD patients and non-COPD (ex-)smokers that were stimulated with nontypeable Haemophilus influenzae (NTHi). In addition, the effect of cigarette smoke on AMP expression and the activation of signaling pathways was determined. COPD cell cultures displayed reduced antibacterial activity, whereas smoke exposure suppressed the NTHi-induced expression of AMPs and further increased IL-8 expression in COPD and non-COPD ...
Chronic obstructive pulmonary disease (COPD) is a systemic inflammatory disorder with a high morbidity and mortality rate, characterized by not fully reversible airflow restriction [1,2]. COPD is not a disorder limited to the lungs and it proceeds with extrapulmonary comorbidities due to systemic inflammation. Among these, cardiovascular diseases (CVDs) are the most frequently encountered disorders, also contributing to mortality rates in COPD [3]. The publications related to the association of these two disorders are limited, and the information available is not clear. The leading cause of cardiac comorbidity frequently observed in COPD may be shared risk factors such as smoking, advanced age, and sedentary lifestyle. Another mechanism is the development of systemic inflammatory response due to the release of acute phase reactants such as C-reactive protein (CRP), fibrinogen, serum amyloid A, surfactant protein D, and leucocytes following local inflammation in the airway and vascular lumen ...
[496 Pages Report] Check for Discount on Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2017 report by Global Markets Direct. Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline...
Define chronic obstructive pulmonary disease: pulmonary disease (such as emphysema or chronic bronchitis) that is characterized by chronic typically …
Everything you need to know about chronic obstructive pulmonary disease (copd). What is (chronic obstructive pulmonary disease (copd)) and where is it?
ERJ Express. Published on October 10, 2013 as doi: / Impact of symptoms of anxiety and depression on COPD Assessment Test (CAT) scores Authors Christina W. Hilmarsen* 1, Sarah Wilke*
This quality standard covers the assessment, diagnosis and management of chronic obstructive pulmonary disease (COPD). It does not cover prevention, screening or case finding. For more information see the COPD topic overview.. This quality standard was previously called chronic obstructive pulmonary disease quality standard.. In February 2016, this quality standard was updated. A new statement on emergency oxygen during an exacerbation has been added and the other quality statements have been updated.. This quality standard has been updated. The topic was identified for update following the annual review of quality standards in 2014. The review identified that there had been changes in the areas for improvement for COPD. For further information about the update, including statements from the 2011 quality standard that are no longer national priorities for improvement but are still underpinned by current accredited guidance, see update information.. ...
TY - JOUR. T1 - Clinical research in chronic obstructive pulmonary disease. T2 - Needs and opportunities. AU - Croxton, Thomas L.. AU - Weinmann, Gail G.. AU - Senior, Robert M.. AU - Wise, Robert A.. AU - Crapo, James D.. AU - Buist, A (Sonia). PY - 2003/4/15. Y1 - 2003/4/15. N2 - Chronic obstructive pulmonary disease (COPD) is a common condition, and one difficult to manage. Available treatments, other than smoking cessation, are only minimally effective, and the knowledge basis for clinical decision making is limited. To identify areas in which further clinical research may lead to significant improvements in the care of patients with COPD, the National Heart, Lung, and Blood Institute convened a Working Group, entitled "Clinical Research in COPD: Needs and Opportunities," on March 21-22, 2002. This group of experts identified important questions in the field and made the following recommendations: (1) establish a multicenter Clinical Research Network to perform multiple, short-term clinical ...
Genetic and Environmental Determinants of Chronic Obstructive Pulmonary Disease. Larson, Roger K.; Barman, Martin L.; Keuppers, Friedrich; Fudenberg, Hugh // Annals of Internal Medicine;May70, Vol. 72 Issue 5, p627 The prevalence of abnormalities of pulmonary function among 156 relatives of 61 patients with chronic obstructive pulmonary disease was found to be significantly higher than the prevalence in a control group of their spouses. No relationship of this increased familial prevalence to... ...
Free Chronic Obstructive Pulmonary Disease News Widget easy download for websites. Regularly updated dynamic Chronic Obstructive Pulmonary Disease news content.
Chronic Obstructive Pulmonary Disease, Second Edition, by T L Petty, Sir William Petty starting at $2.08. Chronic Obstructive Pulmonary Disease, Second Edition, has 1 available editions to buy at Alibris
Rossoff, L.J.; Csima, A.; Zamel, N., 1979: Reproducibility of maximum expiratory flow in severe chronic obstructive pulmonary disease
Background To determine generic utilities for Spanish chronic obstructive pulmonary disease (COPD) patients stratified by different classifications: GOLD 2007, GOLD 2013, GesEPOC 2012 and BODEx index.
Chronic obstructive pulmonary disease (COPD), also known as chronic obstructive lung disease (COLD), and chronic obstructive airway disease (COAD), is a collection of diseases which make breathing gradually more difficult. Symptoms of COPD include difficulty breathing and cough, in particular coughing up lots of phlegm.[1] It is usually caused by smoking cigarettes, and around half of people who smoke for their whole lives will develop COPD.[2] Air pollution can be another cause, particularly in countries where indoor fires are used without ventilation. At the beginning of the disease, the difficulty breathing is only noticeable when exercising, but over many years it gradually becomes worse, until there is difficulty breathing even when sitting or lying down.[3] It can also lead to infections of the lung, which may be serious enough to cause death. The most important step in treating COPD is to stop smoking.[4] Exercise and medications can also help. The most commonly used medications are ...
In this large prospective study of over 4800 individuals with mild to moderate COPD, serum CRP levels were found to be a significant predictor of all-cause mortality. The risk increased linearly along the CRP gradient, even after adjustments for potential confounders such as age, race, sex, cigarette smoking, and FEV1 (both FEV1 at baseline and the rate of decline in FEV1), indicating that serum CRP provides incremental prognostic information to these traditional markers of morbidity and mortality. Its discriminative power for all-cause mortality was greatest during the first year of measurement and decayed over time. Combined with age, race, and BMI, CRP levels produced a C statistic of 0.82 for 1 year mortality, suggesting the potential usefulness of serum CRP levels in estimating the prognosis of patients with COPD. In addition, serum CRP levels were significantly associated with cardiovascular events (both fatal and non-fatal) and with cancer specific causes of mortality.. The results of the ...